— Know what they know.
Not Investment Advice

ALPN NASDAQ

Alpine Immune Sciences, Inc.
1W: +0.0% 1M: +0.7% 3M: +113.0% 1Y: +655.5% 3Y: +373.2% 5Y: +991.9%
$64.97
Last traded 2024-05-20 — delisted
NASDAQ · Healthcare · Biotechnology · $4.5B mcap · 48M float · 5.14% daily turnover

Balance Sheet Trends

Total Assets
$380M +32.5% ▲
5Y CAGR: +47.2%
Total Liabilities
$52M -51.6% ▼
5Y CAGR: +38.2%
Shareholders Equity
$328M +82.8% ▲
5Y CAGR: +49.0%
Cash & Investments
$327M +37.8% ▲
5Y CAGR: +44.3%
Total Debt
$10M -30.3% ▼
5Y CAGR: +18.7%
Net Debt
-$34M -4124.5% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$16M$35M$68M$13M$44M
Short-Term Investments$24M$71M$94M$224M$283M
Cash & ST Investments$41M$106M$162M$238M$327M
Net Receivables$686K$388K$25M$709K$749K
Inventory-$686K-$388K-$323K-$317K-$167K
Other Current Assets$2M$2M$5M$3M$2M
Total Current Assets$42M$107M$192M$241M$330M
Property, Plant & Equip.$12M$11M$11M$10M$9M
Goodwill & Intangibles$0$0-$11M$0$0
Long-Term Investments$254K$26M$53M$35M$41M
Other Non-Current Assets$0$254K$11M$254K$268K
Total Non-Current Assets$12M$37M$64M$46M$50M
Total Assets$54M$144M$256M$287M$380M
— Liabilities —
Accounts Payable$2M$582K$3M$4M$4M
Short-Term Debt$418K$3M$5M$4M$912K
Deferred Revenue$1M$32M$52M$36M$16M
Other Current Liabilities$5M$6M$9M$14M$21M
Total Current Liabilities$9M$41M$70M$58M$42M
Long-Term Debt$16M$19M$14M$10M$9M
Other Non-Current Liab.$0-$8M-$3M$39M$0
Total Non-Current Liabilities$16M$41M$65M$49M$10M
Total Liabilities$25M$82M$135M$107M$52M
— Equity —
Common Stock$19K$24K$30K$46K$60K
Retained Earnings-$88M-$116M-$166M-$224M-$256M
Accumulated OCI$10K$53K-$273K-$1M$397K
Total Stockholders Equity$29M$62M$121M$179M$328M
Total Liabilities & Equity$54M$144M$256M$287M$380M
— Key Metrics —
Total Debt$16M$23M$20M$14M$10M
Net Debt$233K-$12M-$48M$845K-$34M
Total Investments$25M$96M$147M$260M$324M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms